Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a Phase 1 clinical trial titled ‘A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)’. The study aims to evaluate the safety and tolerability of the experimental drugs REGN5837 and odronextamab in treating aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs), with the goal of determining the recommended dose for phase 2 trials.
The intervention involves administering two experimental drugs, REGN5837 and odronextamab, via intravenous infusion. These drugs are designed to target specific proteins on cancer cells, potentially improving treatment outcomes for patients with relapsed or refractory B-NHLs.
This interventional study follows a single-group assignment model with no masking, focusing primarily on treatment. The study is currently in the recruitment phase, indicating active participant enrollment.
The study began on December 14, 2022, with an estimated primary completion date in 2025. The last update was submitted on August 21, 2025, suggesting ongoing progress and adjustments to the study protocol.
For investors, this study represents a significant step in Regeneron’s oncology pipeline, potentially influencing the company’s stock performance positively if successful outcomes are reported. The trial’s progress could also impact investor sentiment, especially in comparison to competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.